Fusion Antibodies Ltd (FAB) ORD GBP0.04
2.50p
(2.13%)
- Add to watchlist
- Create an alert
- This stock can be held in a
2.50p
(2.13%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
2.50p
(2.13%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Fusion Antibodies soars on Covid-19 test progress
18 September 2020 09:48
(Sharecast News) - Fusion Antibodies shares soared after the antibody specialist said it had made progress on developing coronavirus antigen tests.
-
Fusion Antibodies FY revenues continue to grow in 2020
6 July 2020 10:41
(Sharecast News) - Pre-clinical antibodies group Fusion Antibodies said on Monday that revenues had continued to grow over the year ending on 31 March.
-
Fusion Antibodies raises £3m for Covid-19 research
28 April 2020 11:19
(Sharecast News) - Fusion Antibodies has raised £3m from investors to extend its research to cover potential treatments for Covid-19.
-
Fusion Antibodies sees 'favourable trends' continue in H2
29 January 2020 09:32
(Sharecast News) - Pre-clinical therapeutic drug and diagnostics firm Fusion Antibodies said on Wednesday that trading in the third quarter of the financial year had continued the "favourable...
-
Fusion Antibodies cuts losses after revenue leaps
2 December 2019 11:27
(Sharecast News) - Fusion Antibodies on Monday reported a narrowed loss after revenue more than doubled following the launch of its RAMP service.
-
Fusion Antibodies pleased with progress in first half
22 October 2019 15:13
(Sharecast News) - Preclinical antibody discovery company Fusion Antibodies updated the market on the six months ended 30 September on Tuesday, reporting continued revenue growth amid the commercial roll out...
-
Fusion Antibodies soars as optimism overshadows widened loss
2 July 2019 11:40
(Sharecast News) - Fusion Antibodies\' shares leapt on Tuesday as it reported a significant increase in second half orders, although the company still registered a wider annual loss and a drop in revenues.
-
Fusion Antibodies revenues soar in strong second half
17 April 2019 10:46
(Sharecast News) - Pharmaceutical research outfit Fusion Antibodies reported a strong second half on Wednesday, driven by a significant increase in orders.
-
Fusion Antibodies dives as revenues falter
25 February 2019 10:43
(Sharecast News) - Fusion Antibodies' shares plummeted on Monday after the company warned of failing revenues due to uncertainty surrounding the timing of "a number of potential substantial...
-
Fusion Antibodies launches new 'RAMP' platform
17 December 2018 14:51
(Sharecast News) - Pharmaceutical contract research organisation Fusion Antibodies launched its new 'Rational Affinity Maturation Platform' (RAMP) at the Antibody Engineering Conference in San...
-
Fusion Antibodies sees losses widen throughout 'challenging' first half
26 November 2018 10:17
(Sharecast News) - Pharmaceutical research outfit Fusion Antibodies saw losses widen sharply throughout the first half of its trading year after revenues more than halved.
-
Fusion Antibodies gets dragged to a loss as non-recurring items skyrocket
16 August 2018 08:10
(Sharecast News) - Contract researcher Fusion Antibodies saw revenues hit £2.7m in its last trading year but was unable to chalk up a profit.
Company announcements Announcements
-
Total Voting Rights
26 February 2021 17:00
Fusion Antibodies
-
Directorate Change
16 February 2021 07:00
Fusion Antibodies
-
Holding(s) in Company
12 February 2021 09:05
Fusion Antibodies
-
Director/PDMR Shareholding
22 January 2021 15:37
Fusion Antibodies
-
Second Price Monitoring Extn
12 January 2021 16:41
Fusion Antibodies
-
Price Monitoring Extension
12 January 2021 16:35
Fusion Antibodies
-
Half-year Report
20 November 2020 07:00
Fusion Antibodies
-
Price Monitoring Extension
17 November 2020 14:00
Fusion Antibodies
-
Notice of Results
12 November 2020 07:00
Fusion Antibodies
-
Second Price Monitoring Extn
28 October 2020 16:41
Fusion Antibodies
-
Price Monitoring Extension
28 October 2020 16:36
Fusion Antibodies
-
Receipt of grants from Invest Northern Ireland
27 October 2020 07:00
Fusion Antibodies
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.